# First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients

> **NCT04537286** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 90 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)

## Key facts

- **NCT ID:** NCT04537286
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-25
- **Primary completion:** 2024-09-15
- **Final completion:** 2024-10-15
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2024-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04537286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04537286, "First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04537286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*